Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

eMI Aesthetics vs FuturHealth

eMI Aesthetics
Graded #104

Higher grade

vs+4.700000000000003
FuturHealth
Graded #215

Lower grade

The verdict

eMI Aesthetics takes it — 70.3/100 to 65.6/100.

eMI Aesthetics grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. eMI Aesthetics is a US direct-to-consumer telehealth brand offering doctor-guided GLP-1 weight loss programs to eligible patients in all 50 states.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueeMI Aesthetics +13
73
60
Dose & formulationeMI Aesthetics +3
84
81
Clinical oversighteMI Aesthetics +3
70
67
Labs & monitoringFuturHealth +10
51
61
FulfillmenteMI Aesthetics +15
77
62
Contract termsEven
55
55
eMI Aesthetics · left barFuturHealth · right bar

The numbers

MetriceMI AestheticsFuturHealth
WeighScore70.3/10065.6/100
GradeCC
Scorecard rank#104#215
Semaglutide$179/mo (all doses, compounded)$199/mo (compounded)
TirzepatideNot disclosedNot disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessYesYes
Oral / sublingualYesYes
eMI Aesthetics

Graded #104 · C

Strengths

  • Available to eligible patients in all 50 states
  • Offers both semaglutide and tirzepatide, plus an oral semaglutide option
  • Intake and provider visits run through OpenLoop Health, an established telehealth network

Where it loses points

  • Full per-drug pricing is not shown before intake; only an 'as low as 179/month' starting rate is published
  • No fill pharmacy or named medical director is publicly listed
  • Support appears limited to email, with no phone number or hours published
FuturHealth

Graded #215 · C

Strengths

  • LegitScript Certified and HITRUST Certified
  • Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
  • Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
  • Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths

Where it loses points

  • Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
  • BBB complaints describe recurring charges without medication received — confirm cancellation flow first
  • Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
  • Pricing not shown until after the qualification questionnaire or portal login
  • Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard